Johnson & Johnson (NYSE:JNJ) announces
that the FDA approved a new indication for Invokana to reduce the risk
of end-stage kidney disease and treat diabetic kidney disease.
The company says Invokana is now the only type 2
diabetes medicine indicated to both treat diabetic kidney disease and
reduce the risk of hospitalization for heart failure in patients with
T2D and DKD.
Source: Press Release
JNJ +0.26% premarket to $128.94.
https://seekingalpha.com/news/3502565-johnson-and-johnson-discloses-positive-invokana-development
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.